Roche Holding AG (RHHBF)
OTCMKTS
· Delayed Price · Currency is USD
351.07
0.00 (0.00%)
Feb 21, 2025, 3:00 PM EST
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
n/a
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
266.18B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 21.77M |
| SANUWAVE Health | 29.30M |
Roche Holding AG News
- 2 days ago - Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology - GlobeNewsWire
- 4 days ago - Roche goes beyond diagnostics innovation and builds partnerships for proactive healthcare - South China Morning Post
- 4 days ago - Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche - Business Wire
- 9 days ago - Roche upgraded by UBS to buy on growth outlook - Seeking Alpha
- 10 days ago - FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) - GlobeNewsWire
- 10 days ago - FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) - Business Wire
- 16 days ago - New England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis - GlobeNewsWire
- 16 days ago - New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis - Business Wire